Concord Biotech
add_icon

Concord Biotech

1,315.10
-32.40
(-2.40%)
Market Cap
13,758.08 Cr
PE Ratio
54.16
Volume
2,82,224.00
Day High - Low
1,351.10 - 1,305.10
52W High-Low
2,083.40 - 987.00
ann
There are 1 new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
13,758.08 Cr
EPS
24.78
PE Ratio
54.16
PB Ratio
6.96
Book Value
192.81
EBITDA
364.12
Dividend Yield
0.56 %
Industry
Healthcare
Return on Equity
20.50
Debt to Equity
0.00
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+33.33 %
+33.33 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Concord Biotech invests ₹6.3 crore in FSGE Renewable Power for a hybrid project. The move aims to reduce carbon footprint and energy costs.
neutral
Concord Biotech officials will meet investors in Mumbai on June 24-25, 2026. The non-deal roadshow is organised by Kotak Institutional Equities.
neutral
Concord Biotech Ltd will hold a virtual analyst and institutional investor meeting on June 17, 2026, at 10:30 AM IST. Discussions will rely on publicly available information.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,838.30
#1 4,41,069.75
38.02
#1 58,220.10
6.38
#1 11,565
25.80
59.20
6,743.00
1,79,005.46
69.96
10,560.00
8.73
2,520
13.44
55.09
4,429.80
1,49,924.56
70.32
13,886.20
20.34
2,138
-26.91
50.44
1,351.80
1,09,195.79
28.36
29,044.60
2.24
3,870
-55.32
43.59
1,070.80
1,07,747.54
21.10
26,719.70
13.65
5,242
7.82
55.72
2,351.60
1,07,478.28
#1 19.87
27,487.50
19.98
5,345
#1 87.72
62.62
1,272.10
1,06,174.94
25.45
33,593.30
-0.44
3,998
-86.05
45.29
2,414.20
99,659.40
51.25
14,277.60
12.03
1,750
31.75
56.36
1,497.80
86,992.47
23.93
33,384.70
3.21
3,376
1.99
59.92
1,412.90
76,276.34
83.13
6,867.80
#1 22.01
890
21.18
63.84
Growth Rate
Revenue Growth
-15.24 %
Net Income Growth
-30.47 %
Cash Flow Change
-7.89 %
ROE
1.59 %
ROCE
0.49 %
EBITDA Margin (Avg.)
-25.89 %

Quarterly Financial Results

Quarterly Financials
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
195
165
250
285
208
271
252
330
228
320
261
439
219
263
288
341
Expenses
116
122
131
146
123
147
135
187
135
177
146
241
143
159
183
208
EBITDA
79
44
119
139
85
124
117
143
93
144
115
198
77
104
105
134
Operating Profit %
36 %
24 %
46 %
47 %
37 %
44 %
44 %
41 %
38 %
43 %
40 %
44 %
30 %
36 %
34 %
36 %
Depreciation
14
13
14
14
13
13
14
14
13
13
13
15
18
18
19
20
Interest
1
1
1
2
1
1
1
1
0
0
0
0
0
0
0
0
Profit Before Tax
64
30
105
124
71
110
103
129
80
130
101
184
59
86
86
114
Tax
15
8
27
32
17
29
26
34
20
35
25
43
15
23
23
26
Net Profit
49
22
77
92
55
81
78
95
60
96
76
140
44
63
64
89
EPS in ₹
4.71
2.10
7.40
8.75
5.21
7.74
7.41
9.08
5.70
9.15
7.26
13.42
4.21
6.03
6.08
8.46

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
2026
Total Assets
941
1,183
1,313
1,514
1,701
2,034
2,235
Fixed Assets
240
546
573
593
575
795
871
Current Assets
539
607
633
728
896
1,135
1,250
Capital Work in Progress
141
18
74
173
212
51
78
Investments
199
141
74
137
246
335
326
Other Assets
361
477
592
611
668
854
0
Total Equity & Liabilities
941
1,183
1,313
1,514
1,701
2,034
2,235
Current Liabilities
115
106
155
192
142
184
169
Non Current Liabilities
55
77
54
32
32
38
51
Total Equity
770
999
1,103
1,290
1,527
1,813
2,017
Reserve & Surplus
761
990
1,094
1,280
1,516
1,802
2,007
Share Capital
10
10
10
11
11
11
11

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
-1
3
-5
3
12
-14
Investing Activities
-114
-195
-112
-158
-155
-160
Operating Activities
155
167
208
246
266
245
Financing Activities
-43
31
-100
-85
-99
-99

Share Holding

% Holding
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
FIIs
0.00 %
7.30 %
0.00 %
6.48 %
7.11 %
8.10 %
8.33 %
9.35 %
9.11 %
8.03 %
7.58 %
7.80 %
DIIs
4.89 %
8.18 %
8.13 %
8.46 %
10.40 %
9.89 %
9.66 %
9.16 %
8.87 %
9.55 %
9.58 %
9.22 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
13.33 %
6.78 %
6.76 %
7.08 %
7.64 %
7.33 %
7.33 %
6.94 %
7.43 %
7.77 %
8.11 %
8.09 %
Others
37.69 %
33.66 %
41.03 %
33.90 %
30.76 %
30.61 %
30.59 %
30.47 %
30.51 %
30.56 %
30.64 %
30.81 %
No of Share Holders
3,77,572
1,00,927
87,486
83,296
80,737
84,298
82,004
81,219
82,045
82,650
81,815
82,249

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 6.83 8.75 10.7 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.52 1.05 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Jun 2024 DIVIDEND Dividend
₹ 8.75 /share
21 Jun 2024 1,460.10 1,559.25
29 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Jun 2024 1,460.10 1,549.05
11 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2024 1,812.25 1,850.00
13 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Feb 2025 2,125.70 2,119.00
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2025 1,532.10 1,635.70
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 1,739.70 1,633.10
03 Sept 2025 DIVIDEND Dividend
₹ 10.70 /share
03 Sept 2025 1,635.70 1,691.15
09 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Sept 2025 1,648.30 1,610.20
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 1,394.90 1,462.85
11 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Feb 2026 1,168.20 1,283.50
29 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2026 1,153.30 1,099.40

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing Facility8 days ago
Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets 5 Mg And 10 Mg10 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 05, 2026
Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Mycophenolate Mofetil For Oral Suspension USP 200 Mg/MlJun 02, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 01, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 30, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2026
Corporate Action-Board approves DividendMay 29, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2026
Audited Standalone And Consolidated Financial Results For The Fourth Quarter And Financial Year Ended On March 31 2026May 29, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday May 29 2026May 29, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2026
Board Meeting Intimation for Meeting To Be Held On Friday May 29 2026 Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 23, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2026
Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 02, 2026
Closure of Trading WindowMar 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 11, 2026
Disclosure Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2026
Unaudited Standalone And Consolidated Financial Results For The Third Quarter And Nine Months Ended On December On 31 2025Feb 11, 2026
Appointment of Company Secretary and Compliance OfficerFeb 11, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Wednesday February 11 2026Feb 11, 2026
Clarification Regarding Increase In VolumeFeb 09, 2026
Clarification sought from Concord Biotech LtdFeb 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2026
Board Meeting Intimation for Board Meeting Intimation For Financial ResultsFeb 06, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Closure of Trading WindowDec 26, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerDec 24, 2025
Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations 2015Dec 18, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 18, 2025
Board Meeting Outcome for Appointment Of CFO And KMPDec 18, 2025
Announcement under Regulation 30 (LODR)-CessationDec 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 08, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Financial Results For The Period Ended 30 September 2025Nov 13, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 13/11/2025Nov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 08, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
1.45%
15000
0.16%
1.45%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.17%
140
-0.02%
-0.03%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.17%
22
-0.02%
-0.02%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.06%
12
-0.01%
0.00%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.06%
9
0.00%
0.00%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.02%
2
0.00%
0.00%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct-Growth
0.17%
0
0.00%
-0.02%
Invesco India Manufacturing Fund Direct-Growth
0.00%
0
0.00%
0.00%
Invesco India ELSS Tax Saver Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas Business Cycle Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas Children's Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas Conservative Hybrid Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas ELSS Tax Saver Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas Equity Savings Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.17%
0
0.00%
-0.02%
Baroda BNP Paribas Innovation Fund Direct-Growth
0.96%
0
0.00%
0.96%
Baroda BNP Paribas Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Baroda BNP Paribas Retirement Fund Direct-Growth
0.00%
0
0.00%
0.00%
Canara Robeco Manufacturing Fund Direct-Growth
0.42%
0
0.00%
-0.05%
DSP Healthcare Fund Direct-Growth
1.58%
0
0.00%
-0.23%
DSP Nifty 500 Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
Bandhan Midcap Fund Direct-Growth
0.00%
0
0.00%
0.00%
DSP Small Cap Direct Plan-Growth
0.76%
0
0.00%
-0.09%
Edelweiss ELSS Tax Saver Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
60.45
ATR(14)
Less Volatile
54.66
STOCH(9,6)
Neutral
77.59
STOCH RSI(14)
Neutral
61.58
MACD(12,26)
Bullish
8.55
ADX(14)
Strong Trend
29.71
UO(9)
Bearish
49.33
ROC(12)
Uptrend And Accelerating
9.45
WillR(14)
Neutral
-24.97

About Concord Biotech

Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies...more
Listing Date
18 Aug, 2023(2 Years, 33 days)
Chairperson NameSUDHIR JAIRAM VAID